Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs
Elisabetta Degasperi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Serena Pelusi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Marta Borghi(University of Milan), Luca Valenti(University of Milan), E. Galmozzi(University of Milan), R. Soffredini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Riccardo Perbellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Massimo Iavarone(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), F. Facchetti(University of Milan), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Angelo Sangiovanni(Ospedale Maggiore)
Cited by 67
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789